The store will not work correctly when cookies are disabled.
(3-Benzothiazol-2-ylmethyl-5-fluoro-4-oxo-3,4-dihydro-phthalazin-1-yl)-acetic acid
ID: ALA20440
Chembl Id: CHEMBL20440
PubChem CID: 14810764
Max Phase: Preclinical
Molecular Formula: C18H12FN3O3S
Molecular Weight: 369.38
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(O)Cc1nn(Cc2nc3ccccc3s2)c(=O)c2c(F)cccc12
Standard InChI: InChI=1S/C18H12FN3O3S/c19-11-5-3-4-10-13(8-16(23)24)21-22(18(25)17(10)11)9-15-20-12-6-1-2-7-14(12)26-15/h1-7H,8-9H2,(H,23,24)
Standard InChI Key: LBKGISZTPYHDRI-UHFFFAOYSA-N
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 369.38 | Molecular Weight (Monoisotopic): 369.0583 | AlogP: 2.82 | #Rotatable Bonds: 4 |
Polar Surface Area: 85.08 | Molecular Species: ACID | HBA: 6 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 4.02 | CX Basic pKa: 2.51 | CX LogP: 2.85 | CX LogD: -0.13 |
Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.60 | Np Likeness Score: -1.87 |
References
1. Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH.. (1991) Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners., 34 (1): [PMID:1899452] [10.1021/jm00105a018] |